TY - JOUR
AR - JSO-2020-3-103
TI - Isolated Limb Perfusion in the Treatment of In-Transit Melanoma Metastases: Are There Predictive Factors for the Outcome?
AU - Bechter , Oliver
AU - Boecxstaens , Veerle
AU - Garmyn , Marjan
AU - Roel, Bolckmans
AU - Stas , Marguerite
AU - Van den , Oord Joost
AU - Wolter , Pascal
JO - Journal of Surgical Oncology
PY - 2020
DA - Mon 11, May 2020
SN - 2674-3000
DO - http://dx.doi.org/10.31487/j.JSO.2020.03.03
UR - https://www.sciencerepository.org/isolated-limb-perfusion-in-the-treatment-of-in-transit-melanoma-metastases_JSO-2020-3-103 
KW - Isolated limb perfusion, melanoma, prognostic factors
AB - Introduction: Isolated limb perfusion (ILP) with delivery of high dose melphalan proved to be efficient in
the treatment of in-transit metastases (ITM). Preoperative factors may carry an impact on patient outcome,
including in-field or local progression-free survival (IPFS), time to distant metastases (TDM) and overall
survival (OS).
Materials and Methods: A retrospective analysis of 83 patients who underwent an ILP at our institution
before the era of efficient upfront systemic therapy in high-risk cases. Patients were classified according to
a modified M.D. Anderson score, with relevance for the outcome: 34 stage III A (patients with satellites
and/or ITM), 31 stage III AB (patients with synchronous regional lymph node metastases and satellites
and/or ITM), 11 at a new stage labelled III A(B) which takes into account a previous history of therapeutic
regional node dissection and actual recurrence in the limb only, and 7 stage IV (metastatic cases with actual
major problem of recurrence in the limb).
Results: Our median follow-up time was 90.1 months (IQR 72.8-151.6). Median IPFS was 16.3 months
(95% CI 9.5-78.5), median TDM 28.8 months (95% CI 15.4-69.6) and median OS 34.6 months (95% CI
21.1-59.5). The strongest significant prognostic factor regarding IPFS was LND before ILP (p=0.02).
However, sex (p=0.03/0.07), LND before ILP (p=0.004/0.11) and some primary tumor characteristics
(Clark level (p=0.15/0.07) and ulceration (p=0.006/0.04)) were prognostic regarding TDM and / or OS.
Conclusion: ILP with melphalan can provide long-term regional and systemic tumor control in a selected
group of patients and should be kept in mind for patients recurring after local surgery or radiotherapy and
resistant to or ineligible for the newer systemic therapies.